CA2635589C - Protease inhibition - Google Patents

Protease inhibition Download PDF

Info

Publication number
CA2635589C
CA2635589C CA2635589A CA2635589A CA2635589C CA 2635589 C CA2635589 C CA 2635589C CA 2635589 A CA2635589 A CA 2635589A CA 2635589 A CA2635589 A CA 2635589A CA 2635589 C CA2635589 C CA 2635589C
Authority
CA
Canada
Prior art keywords
protein
human
kunitz
gaa
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2635589A
Other languages
English (en)
French (fr)
Other versions
CA2635589A1 (en
Inventor
Robert C. Ladner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CA2635589A1 publication Critical patent/CA2635589A1/en
Application granted granted Critical
Publication of CA2635589C publication Critical patent/CA2635589C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2635589A 2005-12-29 2006-12-27 Protease inhibition Active CA2635589C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75490305P 2005-12-29 2005-12-29
US60/754,903 2005-12-29
PCT/US2006/049322 WO2007079096A2 (en) 2005-12-29 2006-12-27 Protease inhibition

Publications (2)

Publication Number Publication Date
CA2635589A1 CA2635589A1 (en) 2007-07-12
CA2635589C true CA2635589C (en) 2017-01-17

Family

ID=38228815

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2635589A Active CA2635589C (en) 2005-12-29 2006-12-27 Protease inhibition

Country Status (14)

Country Link
US (1) US8828703B2 (https=)
EP (1) EP1981519B1 (https=)
JP (2) JP5632126B2 (https=)
AU (1) AU2006332774A1 (https=)
CA (1) CA2635589C (https=)
CY (1) CY1119967T1 (https=)
DK (1) DK1981519T3 (https=)
ES (1) ES2663497T3 (https=)
HU (1) HUE038243T2 (https=)
LT (1) LT1981519T (https=)
PL (1) PL1981519T3 (https=)
PT (1) PT1981519T (https=)
SI (1) SI1981519T1 (https=)
WO (1) WO2007079096A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
ES2348230T3 (es) * 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2386310B1 (en) 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP5362349B2 (ja) 2005-04-15 2013-12-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト タンパク質を精製する方法
JP2010505437A (ja) 2006-10-13 2010-02-25 ノボ ノルディスク ヘルス ケア アーゲー 塩基性タンパク質タグに融合したプロセシング酵素
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
WO2009026539A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
JP2013533206A (ja) * 2008-10-22 2013-08-22 ダイアクス コーポレーション 炎症性障害のための、プロテアーゼ結合タンパク質を含む併用療法
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
AU2010222537B2 (en) * 2009-03-10 2016-06-30 Med Discovery Sa Use of serine protease inhibitors in the treatment of neutropenia
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
US9597379B1 (en) * 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
ES2886531T3 (es) 2013-01-07 2021-12-20 Omniox Inc Formas poliméricas de proteínas H-NOX
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
CA2927695C (en) * 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
PL3110434T3 (pl) 2014-02-24 2019-01-31 Takeda Gmbh Białka fuzyjne uti
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
CA2979974A1 (en) 2015-03-17 2016-09-22 Omniox, Inc. Modulation of tumor immunity by protein-mediated o2 delivery
EP4354146B1 (en) 2015-10-19 2026-04-15 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス， インコーポレイテッド Ｈ−ｎｏｘタンパク質の重合体形態
EP3765459A1 (en) * 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CA3148611A1 (en) * 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
DK4031547T3 (da) 2019-09-18 2024-09-09 Takeda Pharmaceuticals Co Plasmakallikreininhibitorer og anvendelser deraf
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0332640A1 (en) 1986-11-17 1989-09-20 California Biotechnology, Inc. Recombinant alzheimer's amyloid protein
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87172A (en) 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US7078383B2 (en) 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5378614A (en) 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
ATE277081T1 (de) 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
NZ284766A (en) 1994-06-02 1998-06-26 Merrell Pharma Inc Perfluoro amino ketones; medicaments as elastase inhibitors
DE69528591T2 (de) 1994-08-05 2003-02-20 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Herstellung des inhibitors fuer die komplexbildung des gewebefaktors
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5648331A (en) 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
JP3469584B2 (ja) 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
JP2001504709A (ja) 1997-01-31 2001-04-10 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 組織因子経路インヒビター３
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6544760B2 (en) 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
US20020102703A1 (en) 1999-12-29 2002-08-01 Sheppard Paul O. Kunitz domain polypeptide zkun10
WO2001068707A1 (en) 2000-03-13 2001-09-20 Eli Lilly And Company Human hepatocyte growth factor activator inhibitor homologue
US20040152633A1 (en) * 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
AU2002353018A1 (en) 2001-12-03 2003-06-17 Dyax Corporation Library screening
WO2003066824A2 (en) * 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
JP2007528721A (ja) 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−２リガンド
AU2004268144A1 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US20050089515A1 (en) 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US20050164945A1 (en) * 2003-10-21 2005-07-28 Andrew Nixon Endotheliase-1 ligands
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1835926A4 (en) 2004-11-22 2009-04-01 Dyax Corp PLASMINE-INHIBITING THERAPIES

Also Published As

Publication number Publication date
PL1981519T3 (pl) 2018-07-31
JP2009521926A (ja) 2009-06-11
JP2012235793A (ja) 2012-12-06
EP1981519A2 (en) 2008-10-22
US20080255025A1 (en) 2008-10-16
WO2007079096A3 (en) 2008-02-14
JP5632126B2 (ja) 2014-11-26
CY1119967T1 (el) 2018-12-12
US8828703B2 (en) 2014-09-09
DK1981519T3 (en) 2018-02-19
SI1981519T1 (en) 2018-05-31
EP1981519B1 (en) 2017-12-27
WO2007079096A2 (en) 2007-07-12
ES2663497T3 (es) 2018-04-13
HUE038243T2 (hu) 2018-10-29
CA2635589A1 (en) 2007-07-12
LT1981519T (lt) 2018-04-25
AU2006332774A1 (en) 2007-07-12
PT1981519T (pt) 2018-02-23
EP1981519A4 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
CA2635589C (en) Protease inhibition
US6906033B2 (en) Protease inhibitor peptides
US5550213A (en) Inhibitors of urokinase plasminogen activator
EP1325931B1 (en) Inhibitors of human neutrophil elastase
JP5813641B2 (ja) 凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法
JPH11511963A (ja) クニッツタイプのプラスマカリクレイン阻害剤
JPH05508150A (ja) 酸化抵抗性トロンボモジュリン類縁体
JPS63301797A (ja) 組織因子タンパク質を製造するためのデオキシリボ核酸
JPH0584083A (ja) 新規ポリペプチド、それをコードする新規ｄｎａ、新規ポリペプチドの製造方法、新規医薬組成物、および新規酵素阻害方法
US5807980A (en) Bovine pancreatic trypsin inhibitor derived inhibitors of factor VIIa-tissue factor complex
US5827824A (en) Protease-resistant thrombomodulin analogs
US6211341B1 (en) Polypeptide having factor Xa inhibitory activity
WO1994001461A1 (en) BOVINE PANCREATIC TRYPSIN INHIBITOR DERIVED INHIBITORS OF FACTOR Xa
JP3517236B2 (ja) プロテアーゼ−耐性トロンボモジュリン・アナログ
US20030223977A1 (en) Kunitz domain mutants as cathepsin G inhibitors
JP2002517197A (ja) プロテアーゼインヒビターペプチド
AU661515B2 (en) Polypeptide, DNA fragment encoding the same, drug composition containing the same and process for producing the same
JPH08511157A (ja) Ｘａファクター阻害活性を有する新規ポリペプチド
KR20090009796A (ko) 키메라 쿠니츠 도메인 및 그의 용도
US5679770A (en) Polypeptide, DNA fragment encoding the same, drug composition containing the same and process for producing the same

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250715

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251124